Equipment Stanford Medicine has managed to reverse several symptoms associated with autism in mice. modulating the activity of a specific brain circuit with the help of an experimental drug used to treat epilepsy. The study identifies a key point in sensory processing and links it to behaviors characteristic of autism spectrum disorders (ASD).
The authors, whose results are published in Science Advances, they point out that the treated animals showed less hypersensitivity to stimuli, decrease in repetitive behaviors and improvement in social interaction and ability to deal with bullying, in addition to a lower propensity for seizures. Although this research involves animal models, it opens up a promising avenue for study.
What the team discovered: A key piece in the brain's sensory "filter"
The work focuses on the reticular nucleus of the thalamus, a region that acts as a filter between the thalamus and the cortex, regulating the influx of sensory information. In mice modified to model ASD (deficient in the Cntnap2 gene), this area was observed to showed marked hyperactivity to stimuli such as light or gusts of air and, surprisingly, also during social interactions.
In addition, researchers detected spontaneous bursts of activity in this nucleus that led to seizures. This dysregulation provides a common thread: it could simultaneously explain autism-like behaviors and increased risk of epilepsy, two conditions that often occur in the same patients.
How the experimental drug worked and what changed in the mice
To test whether reducing this excessive activity was enough to improve behavior, the team administered Z944, a T-type calcium channel blocker in the experimental phase against seizures. By decreasing the hyperexcitability of the thalamic reticular nucleus, the mice They regained more normal patterns of behavior.
In parallel, a neuromodulation strategy known as DREADD, which allows selective control of neuronal activity using designed receptors and specific drugs. With this technique, inhibit the reticular nucleus reversed the deficits in animals with ASD model, while increase their activity in healthy mice induced autism-like behaviors.
- Less sensory hypersensitivity to light or tactile stimuli.
- Reduction of repetitive behaviors and motor hyperactivity.
- Improvements in sociability and in responding to social situations.
- Decreased susceptibility to seizures.
These results support the idea that processes of ASD and epilepsy overlap in this region, which could explain why both conditions tend to coexist at a higher frequency than in the general population.
Clinical implications, scope and cautions
The study places the Thalamic reticular nucleus as a new therapeutic target potential for ASD. The authors, including John Huguenard (lead author) and Sung-Soo Jang (first author), emphasize that it is not a cure, but rather an approach that allows modulating a circuit involved in several relevant symptoms.
It is important to emphasize that the conclusions come from animal models, so its translation to humans requires clinical trials that evaluate efficacy and safety. Even with this precaution, the fact that Z944 acts on T-type calcium channels and that neuromodulation techniques confirm the causal role of the reticular nucleus strengthens the plausibility of the therapeutic objective.
In terms of public health, associations such as Autism Spain estimates the prevalence of ASD at around 1 in every 100 children.The absence of pharmacological treatments directed at the core of the disorder—beyond symptomatic control—means that discover specific targets in the brain is especially valuable for the future development of therapies.
Stanford's work offers a solid proof of concept: Reducing the hyperactivity of a sensory "filter" in the brain can change key behaviors in a model of autism. In the absence of human studies, the finding fits with the known relationship between the thalamus, cortex, and epilepsy, and opens a path of research for more precise treatments that modulate well-defined neural circuits.
